Repertoire Immune Medicines, a clinical-stage biotech company working to unleash the curative power of the immune system, today announced the addition of three new members to its executive team: Andrea DiFabio, EVP, Chief Legal and Corporate Administration Officer; Tim Harris, Ph.D., Dsc., EVP, Corporate Development and Lucia Celona, EVP, Chief Human Resources Officer. All three members join the company’s leadership team and report to CEO John Cox, with whom they worked at Biogen and Bioverativ.
“In the few weeks since Repertoire Immune Medicines was formed, we’ve consolidated a stellar executive team,” said Mr. Cox. “With the addition of Andrea, Tim and Lucia, the company’s leadership is largely complete. Repertoire Immune Medicines is at an exciting and pivotal stage, and I am confident this team now has the talent and expertise needed to drive the company forward with great success.”
Ms. DiFabio joins Repertoire Immune Medicines from Codiak BioSciences, where she served as Chief Legal Officer and Secretary. Prior to Codiak, she served as Executive Vice President, Chief Legal Officer and Secretary at Bioverativ, where she was integral in the formation and launch of the company through its acquisition by Sanofi. She held multiple positions over the course of 11 years at Biogen, supporting the company’s global product portfolios, commercial launch and business development activities. Previously, Ms. DiFabio held positions of increasing responsibility at Parexel International. She began her career as a litigator for two Boston-area law firms. Ms. DiFabio earned a B.A. from Boston University and a J.D. from Northeastern School of Law.
Dr. Harris has been in biotechnology R&D since 1978 in various roles in large and small companies. He was most recently the Executive Vice President of Research and Development at Bioverativ, where he led the company’s scientific strategy, advancing pipeline programs and optimizing research and development operations. Dr. Harris was a venture partner at SV Life Sciences, where he helped to identify and analyze investment opportunities for its two newest funds. From 2011 to 2016, he held the roles of Senior Vice President, Precision Medicine and Senior Vice President, Translational Medicine and Biochemistry at Biogen, where he established foundational innovative technologies that advanced R&D efforts.
Ms. Celona previously served as Chief People Officer at Apellis Pharmaceuticals, where she was responsible for overseeing the strategy, development and execution of all aspects of the human resources and corporate communications functions. Prior to that she worked at Bioverativ where, as the Chief Human Resources and Communications Officer, she was instrumental in the formation of the company, directing matters relating to talent, organization design, culture, public affairs and employee communications. Prior to Bioverativ, she was at Biogen for 12 years holding numerous HR-related positions, including Vice President, Human Resources for Biogen’s Pharmaceutical Operations and Technology Organization. Ms. Celona has held numerous HR leadership positions in companies, such as Hewlett Packard and Philips Medical Systems. Ms. Celona received a B.A. in accounting from Bentley University and completed the Advanced HR Executive Program at the University of Michigan.
About Repertoire Immune Medicines
Repertoire Immune Medicines, a Flagship Pioneering company, is a clinical stage biotechnology company working to unleash the remarkable power of the human immune system to prevent, treat or cure cancer, autoimmune conditions and infectious diseases. The company is founded on the premise that the repertoire of TCR-antigen codes that drive health and disease represents one of the greatest opportunities for innovation in medical science. The company harnesses and deploys the intrinsic ability of T cells to prevent and cure disease. Repertoire scientists created and developed a suite of technologies for its DECODE discovery and DEPLOY product platforms that allow in-depth characterization of the immune synapse and the ability to rationally design, and clinically develop, multi-clonal immune medicines. The company is currently conducting experimental medicine clinical trials using autologous T cells primed against cancer antigens and tethered to IL-15. To learn more about Repertoire Immune Medicines, please visit our website: www.repertoire.com and follow us on LinkedIn.